| 73.59 -0.3 (-0.41%) | 10-12 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 88.37 | 1-year : | 92.77 |
| Resists | First : | 75.66 | Second : | 79.43 |
| Pivot price | 73.4 |
|||
| Supports | First : | 69.58 | Second : | 57.89 |
| MAs | MA(5) : | 72.58 |
MA(20) : | 73.85 |
| MA(100) : | 77.78 |
MA(250) : | 79.88 |
|
| MACD | MACD : | -0.5 |
Signal : | -0.6 |
| %K %D | K(14,3) : | 27.4 |
D(3) : | 19.9 |
| RSI | RSI(14): 50 |
|||
| 52-week | High : | 97 | Low : | 69.58 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ ANIP ] has closed below upper band by 47.0%. Bollinger Bands are 23.9% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 74.17 - 74.55 | 74.55 - 74.84 |
| Low: | 71.93 - 72.33 | 72.33 - 72.64 |
| Close: | 72.96 - 73.63 | 73.63 - 74.14 |
ANI Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets branded and generic pharmaceutical products in the United States and internationally. The company provides injectables, softgel capsules, and Cortrophin gel, as well as ILUVIEN and YUTIQ products. It also manufactures oral solid dose products, semi-solids, liquids, topicals, controlled substances, and potent products. The company serves its products to national wholesalers, specialty pharmacies, retail pharmacy chains, distributors, mail order houses, group purchasing organizations, and hospitals and healthcare providers. ANI Pharmaceuticals, Inc. was incorporated in 2001 and is headquartered in Baudette, Minnesota.
Mon, 12 Oct 2026
ANI Pharma reports positive phase 4 data for Iluvien in non-infectious uveitis - Seeking Alpha
Mon, 12 Oct 2026
ANI Pharmaceuticals reports Phase 4 eye‑implant trial met both endpoints - Mugglehead Investment Magazine
Mon, 12 Oct 2026
ANI Pharmaceuticals Reports Positive 6- and 24-Month SYNCHRONICITY Data for ILUVIEN in Chronic NIU-PS - Quiver Quantitative
Mon, 12 Oct 2026
After one implant, 79.6% of treated eyes had no inflammation return for two years - Stock Titan
Sat, 10 Oct 2026
ANI Pharmaceuticals Q3 2026 Earnings Date and Estimates - MarketBeat
Thu, 08 Oct 2026
ANI Pharmaceuticals, Inc. (ANIP) Stock Forecasts - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Drug Manufacturers - Specialty & Generic
|
|
| Shares Out | 23 (M) |
| Shares Float | 20 (M) |
| Held by Insiders | 5.4 (%) |
| Held by Institutions | 107.2 (%) |
| Shares Short | 3,490 (K) |
| Shares Short P.Month | 3,360 (K) |
| EPS | 4.61 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 27.87 |
| Profit Margin | 11 % |
| Operating Margin | 14.9 % |
| Return on Assets (ttm) | 5.4 % |
| Return on Equity (ttm) | 20.4 % |
| Qtrly Rev. Growth | 25.8 % |
| Gross Profit (p.s.) | 25.73 |
| Sales Per Share | 42.61 |
| EBITDA (p.s.) | 9.12 |
| Qtrly Earnings Growth | 191.1 % |
| Operating Cash Flow | 189 (M) |
| Levered Free Cash Flow | 132 (M) |
| PE Ratio | 15.92 |
| PEG Ratio | 1.7 |
| Price to Book value | 2.64 |
| Price to Sales | 1.72 |
| Price to Cash Flow | 8.91 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|